Serri O
Neuroendocrinology. 1986;42(6):475-80. doi: 10.1159/000124490.
We have investigated the effects of intravenous administration of a low dose of dopamine (DA) on plasma growth hormone (GH) concentrations in acromegalic patients and normal subjects with the aim of defining the somatotroph responsiveness to peripheral (i.e., outside the blood-brain barrier) specific dopaminergic stimuli. DA (0.02 micrograms/kg/min) was infused for 180 min into 12 acromegalic patients and 10 normal subjects. DA infusion discriminated between two groups of acromegalics. In group I (n = 7), the elevated plasma GH levels (64.1 +/- 29.9 ng/ml, mean basal value +/- SEM) decreased significantly (mean overall GH inhibition, 26% reduction from basal levels; range, 10-49), whereas in group II (n = 5) plasma GH levels (29.8 +/- 12.5 ng/ml) remained elevated (mean GH variation, 8% above baseline; range, 0-15). Plasma GH concentrations showed a significant rebound above baseline values after stopping DA infusion only in group I. In contrast, the responsiveness to TRH was not significantly different between the groups (percentage increase 767 +/- 317% in group I vs. 382 +/- 210% in group II) and they were also comparable with regard to sex, age, glucose tolerance, plasma prolactin (PRL) concentrations and adenoma size. However, the mean duration of the disease was significantly (p less than 0.02) longer in group I (12.8 +/- 2.6 years) than in group II (4.5 +/- 1.5 years). Further, 3 patients with previous radiotherapy for invasive adenomas were nonresponders to DA. In normal subjects, DA infusion had no significant effect on plasma GH levels. It is concluded that: somatotroph responsiveness to DA is not a constant feature of acromegaly.(ABSTRACT TRUNCATED AT 250 WORDS)
我们研究了静脉注射低剂量多巴胺(DA)对肢端肥大症患者和正常受试者血浆生长激素(GH)浓度的影响,目的是确定生长激素细胞对外周(即血脑屏障外)特定多巴胺能刺激的反应性。将DA(0.02微克/千克/分钟)静脉输注180分钟,对象为12例肢端肥大症患者和10名正常受试者。DA输注可区分两组肢端肥大症患者。在第一组(n = 7)中,升高的血浆GH水平(64.1±29.9纳克/毫升,平均基础值±标准误)显著下降(平均总体GH抑制率,较基础水平降低26%;范围为10 - 49),而在第二组(n = 5)中,血浆GH水平(29.8±12.5纳克/毫升)仍保持升高(平均GH变化,比基线高8%;范围为0 - 15)。仅在第一组中,停止DA输注后血浆GH浓度显示出显著高于基线值的反弹。相比之下,两组对促甲状腺激素释放激素(TRH)的反应性无显著差异(第一组增加百分比为767±317%,第二组为382±210%),并且在性别、年龄、糖耐量、血浆催乳素(PRL)浓度和腺瘤大小方面也具有可比性。然而,第一组疾病的平均病程(12.8±2.6年)显著长于第二组(4.5±1.5年)(p < 0.02)。此外,3例曾接受侵袭性腺瘤放疗的患者对DA无反应。在正常受试者中,DA输注对血浆GH水平无显著影响。结论是:生长激素细胞对DA的反应性并非肢端肥大症的恒定特征。(摘要截断于250字)